The Fate of 1,8-cineole as a Chemical Penetrant : A Review
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
The stratum corneum continues to pose the biggest obstacle to transdermal drug delivery. Chemical penetrant, the first generation of transdermal drug delivery system, offers a lot of potential. In order to fully examine the permeation mechanism of 1,8-cineole, a natural monoterpene, this review summarizes the effects of permeation-enhancing medications on drugs that are lipophilic and hydrophilic as well as the toxicity of this substance on the skin and other tissues. For lower lipophilic drugs, 1,8-cineole appears to have a stronger osmotic-enhancing impact. An efficient and secure tactic would be to combine enhancers and dose forms. 1,8-cineole is anticipated to be further developed in the transdermal drug delivery system and even become a candidate drug for brain transport due to its permeability and low toxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Current drug delivery - 21(2024), 5 vom: 15., Seite 697-708 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dao, Ligema [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1 |
|---|
| Anmerkungen: |
Date Completed 11.01.2024 Date Revised 11.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1567201820666230509101602 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356684040 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356684040 | ||
| 003 | DE-627 | ||
| 005 | 20240114233724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1567201820666230509101602 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM356684040 | ||
| 035 | |a (NLM)37165499 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dao, Ligema |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Fate of 1,8-cineole as a Chemical Penetrant |b A Review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2024 | ||
| 500 | |a Date Revised 11.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a The stratum corneum continues to pose the biggest obstacle to transdermal drug delivery. Chemical penetrant, the first generation of transdermal drug delivery system, offers a lot of potential. In order to fully examine the permeation mechanism of 1,8-cineole, a natural monoterpene, this review summarizes the effects of permeation-enhancing medications on drugs that are lipophilic and hydrophilic as well as the toxicity of this substance on the skin and other tissues. For lower lipophilic drugs, 1,8-cineole appears to have a stronger osmotic-enhancing impact. An efficient and secure tactic would be to combine enhancers and dose forms. 1,8-cineole is anticipated to be further developed in the transdermal drug delivery system and even become a candidate drug for brain transport due to its permeability and low toxicity | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 1 | |
| 650 | 4 | |a 8-cineole | |
| 650 | 4 | |a blood-brain barrier | |
| 650 | 4 | |a penetration enhancer | |
| 650 | 4 | |a skin barrier | |
| 650 | 4 | |a toxicity. | |
| 650 | 4 | |a transdermal drug delivery | |
| 650 | 7 | |a Eucalyptol |2 NLM | |
| 650 | 7 | |a RV6J6604TK |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Dong, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Sa, Chula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug delivery |d 2004 |g 21(2024), 5 vom: 15., Seite 697-708 |w (DE-627)NLM159100232 |x 1875-5704 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:5 |g day:15 |g pages:697-708 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1567201820666230509101602 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 5 |b 15 |h 697-708 | ||